Pharmahof Glizide

PHARMAHOF GLIZIDE is a white round-convex tablet with bisect on one side and PHARMAHOF logo marked on the other side. Each tablet contains Glipizide 5 mg.

Pharmacology: Pharmacokinetics: Glipizide is readily absorbed from the gastro-intestinal tract. It is extensively bound to plasma protein and has a half-life of approximately 2 to 4 hours. It is metabolized mainly in the liver and excreted principally in the urine, largely as inactive metabolites.

PHARMAHOF GLIZIDE is indicated in the therapy of maturity onset diabetes mellitus (non-insulin dependent or type II diabetes mellitus) which cannot be controlled by diet alone.

Initially ½-1 tablet daily, given 15-30 minutes before breakfast, then adjust by increment to optimum dose as directed by a physician. Maximum dose is 8 tablets daily in 2 divided doses before breakfast and dinner.

Symptoms of overdose include low blood sugar, tingling of lips and tongue, nausea, yawning, confusion, agitation, tachycardia, sweating, convulsions, stupor and coma. Intoxication with sulfonylureas can cause hypoglycemia and are best managed with glucose administration (oral for milder hypoglycemia or by injection in more severe forms).

Hypersensitivity to glipizide or any component, type II diabetes mellitus with ketoacidosis and type I diabetes mellitus.

Renal or hepatic function impairment. Patients at increased risk of hypoglycemia.

Not recommended for use during pregnancy and lactation.

Gastro-intestinal disturbance such as nausea, vomiting, heart burn, anorexia and diarrhoea. Skin rashes, pruritus and photosensitivity, hypoglycemic coma, other severe effects such as cholestatic jaundice, leucopenia, thrombocytopenia, agranulocytosis and hemolytic anemia.

Anabolic steroids may increase hypoglycemic effect; monitor blood glucose.
ACE inhibitors may increase hypoglycemic effect; monitor blood glucose.
CYP2C8/9 inhibitors may increase the levels/effects of glipizide. Example inhibitors include delavirdine, fluconazole, gemfibrozil, ketoconazole, nicardipine, NSAIDs, pioglitazone and sulfonamides.
H2 antagonists, antacids, oral sodium bicarbonate may increase the hypoglycemic effect; monitor glucose response.
Cyclosporine serum concentration is increased; monitor cyclosporine levels and renal function.
Beta-blockers decrease hypoglycemic effect, mask most hypoglycemic symptoms, decrease glycogenolysis; avoid use in diabetics with frequent hypoglycemic episodes.
Cholestyramine decreases glipizide's absorption; separate administration times.
CYP2C8/9 inducers may decrease the levels/effects of glipizide. Example inducers include carbamazepine, phenobarbital, phenytoin, rifampin, rifapentine and secobarbital.
Ethanol (large amounts) decreases hypoglycemic effect; avoid concurrent use; rare disulfiram reaction.
Rifampin may decrease hypoglycemic effects of glipizide; monitor blood glucose.
Tacrolimus serum concentrations may be increased; monitor tacrolimus serum concentrations and renal function.
Corticosteroids cause hyperglycemia; adjustment of hypoglycemic agent may be necessary.

Store below 30°C. Protect from light and moisture.

Antidiabetic Agents

A10BB07 - glipizide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

D